These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1666 related items for PubMed ID: 19267351

  • 1. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM.
    Cancer Res; 2008 Feb 01; 68(3):861-9. PubMed ID: 18245488
    [Abstract] [Full Text] [Related]

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
    Immunotherapy; 2011 Jun 01; 3(6):735-46. PubMed ID: 21668311
    [Abstract] [Full Text] [Related]

  • 5. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM.
    Cancer Res; 2007 Feb 01; 67(3):1344-51. PubMed ID: 17283172
    [Abstract] [Full Text] [Related]

  • 6. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.
    Immunol Lett; 2005 Jun 15; 99(1):85-93. PubMed ID: 15894116
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM.
    Cancer Res; 2005 May 15; 65(10):4309-19. PubMed ID: 15899823
    [Abstract] [Full Text] [Related]

  • 10. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 11. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini T, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, Bronte V, Scarselli E.
    Cancer Res; 2008 Dec 01; 68(23):9865-74. PubMed ID: 19047167
    [Abstract] [Full Text] [Related]

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 01; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 13. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, Andersen RS, Pisa P.
    Vaccine; 2009 Mar 04; 27(10):1557-65. PubMed ID: 19171173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.
    J Gene Med; 1999 Mar 04; 1(6):400-6. PubMed ID: 10753065
    [Abstract] [Full Text] [Related]

  • 16. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.
    Cancer Res; 2000 Oct 01; 60(19):5522-8. PubMed ID: 11034097
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
    Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Jiang B, Chen H.
    Cancer Lett; 2010 Jul 28; 293(2):254-62. PubMed ID: 20149524
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.